ISAL 2023 | Evolution of clonal hematopoiesis to BPDCN
Peter van Galen
• 21 Mar 2023
Peter van Galen, PhD, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston, MA, comments on the mechanisms driving progression to blastic plasmacytoid dendritic cell neoplasm (BPDCN) from clonal hematopoiesis (CH). Through the use of multiple sequencing technologies, it was found that CH arises from stem cells in the bone marrow which then transit to the skin, where subsequent UV-induced mutations are acquired. The cells then disseminate throughout the body. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
